Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 20/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 20/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 20/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 20/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6233764 | 0.82 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7984800 | 0.76 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6585373 | 0.75 | PDE4A (0.63) | PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL6588638 | 0.74 | PDE4A (0.62) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6228197 | 0.72 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL6590136 | 0.71 | PDE4D (0.98) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8344691 | 0.71 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7450274 | 0.71 | PDE4D (0.66) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6586317 | 0.71 | PDE4B (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6233865 | 0.70 | PDE4D (0.31) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517707-A1 | TREATMENT FOR DEPRESSION AND ANXIETY WITH THE COMBINATION OF A PDE IV INHIBITOR AND AN ANTIDEPRESSANT OR AN ANXIOLYTIC AGENT | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | claimed |
| EP-1515708-A1 | COMBINATIONS OF PDE-V INHIBITORS AND NK1 ANTAGONISTS FOR THE TREATMENT OF DEPRESSION | Pfizer Products Inc. (US) | 2005-03-23 | — | — | EP | claimed |
| US-20040001895-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-01 | — | — | US | claimed |
| US-20030235631-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2003-12-25 | — | — | US | claimed |
| WO-2003105902-A1 | TREATMENT FOR DEPRESSION AND ANXIETY BY THE COMBINATION OF A PDE IV INHIBITOR AND AN ANTIDEPRESSANT OR AN ANXIOLYTIC AGENT | PFIZER PRODUCTS INC. (US) | 2003-12-24 | — | — | WO | claimed |
| WO-2003105815-A1 | COMBINATION OF PDE-V INHIBITORS AND NK1 ANTAGONISTS FOR THE TREATMENT OF DEPRESSION | PFIZER PRODUCTS INC. (US) | 2003-12-24 | — | — | WO | claimed |
| US-20030235631-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040001895-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, ADORA1 | PDE4A 13/4885PDE4B 30/4885PDE4C 64/4885 |
| US-20030235631-A1 | Combination treatment for depression and anxiety | PDE3B, PDE2A, PDE3A | PDE4A 4/4885PDE4B 6/4885PDE4C 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.